About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Nebivolol Versus Carvedilol in Patients With Heart Failure

NCT00511888·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

IRCCS San Raffaele

Age

53–76

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

left ventricular ejection fraction (LVEF) \< 40%;
symptomatic heart failure with functional New York Heart Association (NYHA) class II or III;
arterial hypertension with systolic blood pressure \>140 mmHg and diastolic blood pressure \>85 mmHg;
clinical stability without hospital admission for heart failure in the previous 3 months.

You may not be if

history of asthma or severe chronic obstructive pulmonary disease;
severe liver or kidney diseases;
second-degree or third degree heart block without a permanent pacemaker,
sick sinus syndrome, heart rate \<60 beat/min, systolic blood pressure \<90 mmHg.

The record

StatusTerminated

PhaseNo phase

Taking part160

StartedJan 2004

UpdatedOct 17, 2008

Conditions

Chronic Heart Failure Hypertension

Where1

IRCCS San Raffaele
Rome, rome, Italy

Clareo Health | Nebivolol Versus Carvedilol in Patients With Heart Failure